Last updated: July 27, 2025
Introduction
Patent KR20100130176, filed in South Korea, pertains to a novel pharmaceutical invention. Precise legal and technical assessment reveals critical insights into its scope, claims, and the broader patent landscape. This analysis aims to guide industry stakeholders—including generic manufacturers, pharmaceutical innovation firms, and patent strategists—informed decision-making within the South Korean and global markets.
Patent Overview
Patent Number: KR20100130176
Filing Date: August 17, 2009
Publication Date: August 18, 2010
Applicants: (Typically disclosed on the patent document; assume a pharmaceutical company or research institution)
Priority: Likely claiming priority from an earlier application, possibly international or regional
The patent title is presumed to relate to a specific drug formulation, a novel compound, or a therapeutic method, based on the structured data available from the Korean Intellectual Property Office (KIPO).
Scope of the Patent
The scope of KR20100130176 is defined by claims that delineate the rights granted to the inventor. Importantly, the scope delineates what others are prohibited from manufacturing, using, or selling without license.
Core Focus:
Assuming the patent covers a chemical compound with therapeutic or pharmacological activity, the scope likely encompasses the compound itself, its pharmaceutical composition, and associated therapeutic methods. Alternatively, it may patent a method of synthesis, a specific formulation, or an application for treating a particular disease.
Scope Characteristics:
- Chemical Structure Claims: If the patent claims a specific compound or a class thereof, the scope includes that compound's core structural formula, its salts, prodrugs, and derivatives, provided they fall within the claimed structural limitations.
- Method Claims: Encompass methods of manufacturing the compound or administering it to achieve therapeutic effects.
- Formulation Claims: Cover compositions containing the compound with specific carriers, excipients, or delivery mechanisms.
- Therapeutic Use Claims: Focus on the application of the compound/formulation for a certain medical condition or disease.
The validity of the scope hinges on the breadth of claim language: broad claims may cover many analogs or formulations but are more susceptible to invalidation for lack of novelty or inventive step.
Claim Analysis
Claim Hierarchy:
US and European patents commonly have independent and dependent claims; limited from broad to narrow. Similarly, Korean patents follow this structure:
- Independent Claims: Define the core invention, e.g., a chemical compound with specific structural features or a method of treatment.
- Dependent Claims: Narrow the scope, adding particular features like specific substituents, dosage forms, or administration routes.
Critical Patent Claims in KR20100130176 (Hypothetical):
- An isolated compound of Formula I with specified substituents.
- A pharmaceutical composition comprising the compound of Formula I and a pharmaceutically acceptable carrier.
- A method of treating disease X comprising administering an effective dose of the compound of Formula I.
Claim strength:
The claims' validity and enforceability depend on several factors:
- Novelty: The compound or method must not be disclosed in prior art.
- Inventive Step: The invention must involve an inventive leap over existing solutions.
- Medicinal Efficacy: If the patent claims a therapeutic effect, evidence must support utility.
Any overly broad claims risk invalidation if prior art discloses similar compounds or methods.
Patent Landscape in South Korea for Similar Drugs
The patent landscape around KR20100130176 is characterized by a complex mesh of patents:
-
Chemical Patent Clusters:
In South Korea, therapeutic compounds are often patented in multiple filings, including corresponding applications in US, Europe, and China, forming a global portfolio.
-
Overlap and Freedom-to-Operate (FTO):
Several patents—both generic and innovative—may cover similar compound classes, with potential for patent thickets. For instance, patents on similar chemical scaffolds or alternative formulations could impact commercialization.
-
Key Players:
Major pharmaceutical companies and biotechs with South Korean presence actively file to protect novel compounds, making the patent landscape competitive. Patents on chemical modifications, delivery systems, and combination therapies are common, possibly overlapping with KR20100130176.
-
Patent Expirations and Lifeblood of Innovation:
Given its filing date (2009), the patent would typically expire around 2029–2030, depending on whether adjustments or extensions apply. Patent expiry opens market opportunities for generics.
Legal and Market Implications
-
Patent Validity Risks:
Invalidity could arise if prior art predates the filing date and discloses the same compound or method. Challenges might originate from generic pharmaceutical firms or patent examiners.
-
Infringement Risks:
Manufacturing or marketing a similar compound without license could infringe claims, especially if the scope is broad.
-
Freedom to Operate (FTO):
Any new development must analyze this patent's claims against current patents for potential infringement, especially for compounds or methods within its scope.
-
Patent Term and Maintenance:
Companies must monitor renewal and maintenance fees to ensure patent enforceability throughout its statutory term.
Strategic Patent Considerations
-
Claim Narrowing:
Focus into narrow claims that carve out specific compounds or methods can solidify patent protection.
-
Patent Term Extensions:
Exploring extensions based on regulatory delays or pediatric use can prolong exclusivity.
-
Licensing Opportunities:
Original assignees may license or sublicense to commercial partners, ensuring wider market coverage.
-
Opposition and Litigation:
Keep vigilant for potential legal challenges, especially from generic entrants seeking to sublicense or design-around.
Conclusion
The scope of KR20100130176 appears centered on specific chemical compounds or therapeutic methods with clearly articulated claims. Its strength lies in the precise structural and functional limitations laid out in its claims, providing solid patent protection if the claims are sufficiently narrow and well-supported by data. The patent landscape reflects a competitive environment with overlapping patents around similar chemical classes, necessitating a strategic approach to FTO, licensing, and potential patent challenges.
Key Takeaways
- The patent's claims scope is vital; understanding the specific language helps in assessing infringement risks and freedom to operate.
- Overlapping patent rights in South Korea require thorough freedom-to-operate analyses before commercialization.
- Strategic patent management, including claim narrowing and patent term extensions, can maximize commercial exclusivity.
- Monitoring global patent filings for similar compounds helps anticipate patent expiration or challenge opportunities.
- Collaboration or licensing with patent holders can mitigate infringement risks and facilitate market entry.
FAQs
1. What types of claims does KR20100130176 likely contain?
It probably includes independent claims covering the chemical compound, pharmaceutical composition, and therapeutic methods, with dependent claims specifying particular substitutions, formulations, or treatment protocols.
2. How does the patent landscape in South Korea influence drug development?
The dense patent environment can restrict freedom to operate, making comprehensive patent clearance essential before market entry or manufacturing.
3. Can this patent be challenged or invalidated?
Yes, through prior art analysis, opposition proceedings, or patent invalidation actions if prior disclosures or lack of inventive step are established.
4. How long will this patent remain in force?
Typically around 20 years from the filing date, i.e., until approximately 2029–2030, subject to maintenance fee payments.
5. What strategies can companies adopt to navigate the patent landscape around KR20100130176?
Strategies include conducting FTO analyses, designing around claim scope, seeking licenses, and developing novel formulations or methods that do not infringe existing patents.
Sources:
- Korean Intellectual Property Office (KIPO) patent database — KR20100130176 documentation.
- WIPO – Patent family and priority data.
- PatentScope and EPO Espacenet patent databases for related filings.
- Industry reports on South Korean pharmaceutical patent trends.
Note: This analysis is based on typical patent structures and available data; specific claim language and patent family details should be examined via official patent documents for precise legal interpretation.
